Log In
BCIQ
Print this Print this
 

Carac, 5-fluorouracil

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionMicrosponge formulation of 5-fluorouracil (5-FU)
Molecular Target Thymidylate synthetase (TYMS)
Mechanism of ActionThymidylate synthase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationActinic keratosis
Indication DetailsTreat actinic keratosis (AK)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$422.5M

$422.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/18/2011

$422.5M

$422.5M

0

Get a free BioCentury trial today